期刊文献+

抗肿瘤药物的药物基因组学研究进展 被引量:3

原文传递
导出
摘要 恶性肿瘤是严重威胁人类生命的主要疾病,据2015年发表的我国2011年恶性肿瘤发病和死亡分析,结果显示我国新增恶性肿瘤患者约337万。目前,肿瘤治疗仍然以化疗、放疗和手术治疗为主,其中化疗是治疗肿瘤的主要手段之一。在肿瘤化疗或靶向治疗中,无论是疗效还是毒性反应,都存在较大的个体差异。造成个体差异的原因是多因素的,如性别、年龄、身高和体重等情况,但经研究表明,造成药物反应个体差异的主要原因是基因多态性。如肿瘤细胞(体细胞)的基因情况在很大程度上与药物疗效相关,患者(胚系)基因的情况影响了药物的暴露量和不良反应的发生的程度。
出处 《中华医学杂志》 CAS CSCD 北大核心 2017年第17期1354-1356,共3页 National Medical Journal of China
基金 国家科技支撑计划(2014BA109801) 国家重大新药创制科技重大专项(2012ZX09303012-001) 北京市自然科学基金重点项目(7141010) 中国医学科学院医学与健康科技创新工程(2016-12M-1-001)
  • 相关文献

参考文献4

二级参考文献64

  • 1Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospec- tive studies[J]. J Natl Cancer Inst , 2002, 94(8) :606-616.
  • 2Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estro- gen and progesterone receptor status in invasive breast carcinoma [J]. Cancer, 2004, 101(7) :1490-1500.
  • 3Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the ran- domised trials[ J]. Lancet, 2005, 365 (9472) : 1687-1717.
  • 4Early Breast Cancer Tfialists' Collaborative Group. Tamoxifen for early breast cancer : an overview of the randomised trials [ J ]. Lancet, 1998, 351(9114) :1451-1467.
  • 5Fabian C, Tilzer L, Stemson L. Comparative binding affinities of tamoxifen, 4-hydroxytarnoxifen, and desmethyhamoxifen for estro- gen receptors isolated from human breast eareinoma: correlation with blood levels in patients with metastatic breast cancer [ J ]. Biopharm Drug Dispos, 1981, 2(4) :381-390.
  • 6Lnning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical phar- macokinetics of endocrine agents used in advanced breast cancer [ J ]. Clin Pharmacokinet, 1992, 22 (5) :327-358.
  • 7Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehen- sive evaluation of tamoxifen sequential biotransformation by the human cytochrome 17450 system in vitro: prominent roles for CYP3A and CYP2D6[J]. J Pharmacol Exp Ther, 2004, 310 (3) : 1062-1075.
  • 8Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spels- berg TC. The tamoxifen metabolite, endoxifen, is a potent anties- trogen that targets estrogen receptor alpha for degradation in breast cancer cells [ J ]. Cancer Res, 2009, 69 ( 5 ) : 1722-1727.
  • 9Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhar- gava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin re-uptake inhibitor paroxetine [ J J. J Natl Cancer lnst, 2003, 95 (23) : 1758-1764.
  • 10Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is as- sociated with clinical outcomes of efficacy and hot flashes [ J ]. J Clin Oncol, 2005, 23(36) :9312-9318.

共引文献937

同被引文献34

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部